Showing 1672 results
-
Press release /Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced…
-
Press release /In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[…
-
Press release /Ultibro® Breezhaler® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies Results further support the…
-
Press release /LIBERTY is the first migraine prevention trial of its kind conducted specifically in patients who have tried multiple therapies without success, and are in need of additional treatment options…
-
Press release /Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure Novartis remains committed to…
-
Press release /New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before…
-
Press release /In the FUTURE 1 study, secukinumab showed rapid and significant efficacy in active psoriatic arthritis (PsA) patients, including improvement of skin and joint disease and reduction in progression of…
-
Press release /Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces…
-
Press release /Positive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when initial treatment stopped working CLL is the most…
-
Press release /The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule Novartis and Amgen also plan…